|
|
HLA-A*2402-restricted URLC10-TTK-VEGFR1-VEGFR2 multipeptide vaccine A cancer vacine containing four HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from: URLC10 (up-regulated lung cancer 10), TTK (TTK protein kinase), and VEGFRs (vascular endothelial growth factor receptors) 1 and 2. Upon administration, URLC10-TTK-KOC1-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing URLC10, TTK, VEGFR 1 and 2 peptides, resulting in cell lysis and decreased tumor growth. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Previous: | HLA-A*0201-restricted VEGFR1 peptide vaccine, HLA-A*0201-restricted VEGFR1-VEGFR2 multipeptide vaccine, HLA-A*2402-restricted KOC1-TTK-CO16-DEPDC1-MPHOSPH1 multipeptide vaccine, HLA-A*2402-restricted URLC10-KOC1-VEGFR1-VEGFR2 multipeptide vaccine, HLA-A*2402-restricted URLC10-TTK-KOC1 multipeptide vaccine | Next: | HLA-A*2402-restricted VEGFR1 peptide vaccine, HLA-A*2404-restricted RNF43-TOMM34-VEGFR1-VEGFR2 multipeptide vaccine, HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine, HLA-A2, A3-restricted FGF-5 peptides/Montanide ISA-51 vaccine, Hodgkin's antigens-GM-CSF-expressing cell vaccine |
|
|